High-Dose VX-548 Reduces Acute Pain Over 48 Hours
FRIDAY, Aug. 4, 2023 (HealthDay News) -- High-dose VX-548, an oral, highly selective inhibitor of the Nav1.8 voltage-gated sodium channel, reduces acute pain over 48 hours after abdominoplasty and bunionectomy, according to a study published in the Aug. 3 issue of the New England Journal of Medicine.
Jim Jones, M.D., Pharm.D., from Vertex Pharmaceuticals in Boston, and colleagues conducted two phase 2 trials involving participants with acute pain after abdominoplasty or bunionectomy. In the abdominoplasty trial, 303 patients were randomly assigned to receive a 100-mg oral loading dose of VX-548, followed by a 50-mg maintenance dose every 12 hours (high-dose group); a 60-mg loading dose of VX-548, followed by a 30-mg maintenance dose every 12 hours (middle-dose group); hydrocodone bitartrate-acetaminophen (5 mg of hydrocodone bitartrate and 325 mg of acetaminophen every six hours); or oral placebo every six hours in a 1:1:1:1 ratio. In the bunionectomy trial, 274 participants were randomly assigned to receive oral high-dose VX-548; middle-dose VX-548; low-dose VX-548 (a 20-mg loading dose, followed by a 10-mg maintenance dose every 12 hours); oral hydrocodone bitartrate-acetaminophen; or oral placebo every six hours in a 2:2:1:2:2 ratio.
The researchers found that in the time-weighted sum of the pain-intensity difference during the 48-hour period, the least-squares mean difference between the high-dose VX-548 and placebo groups was 37.8 and 36.8 after abdominoplasty and bunionectomy, respectively. In both trials, results were similar for those receiving lower doses of VX-548 and placebo. Common adverse events with VX-548 were headache and constipation.
"In two phase 2 clinical trials of postoperative pain, as compared with placebo, the highest dose, but not lower doses, of VX-548 reduced pain over a 48-hour period," the authors write.
Several authors disclosed ties to pharmaceutical companies, including Vertex Pharmaceuticals, the developer of VX-548.
Abstract/Full Text (subscription or payment may be required)
Editorial 1 (subscription or payment may be required)
Editorial 2 (subscription or payment may be required)
Related Posts
Second Trimester Prenatal Testing: An Ob-Gyn Shares What To Expect
Prenatal testing is important to monitor you and your baby’s health, but exactly...
Kids With Eczema May Need Further Allergy Tests
FRIDAY, Sept. 29, 2023 (HealthDay News) -- Some children who have a common form...
Unos cambios genéticos hicieron que la gripe aviar de esta temporada fuera más grave
VIERNES, 2 de junio de 2023 (HealthDay News) -- Unas mutaciones genéticas...
Data Shows 2 Biggest Factors for Cancer Risk
MONDAY, Aug. 8, 2022 (HealthDay News) – Smoking and older age are the two most...